Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human normal immunoglobulin G
- Development stage
- Approved
- Lead developer
- CSL Behring
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Human normal immunoglobulin G is a purified preparation of polyclonal IgG antibodies derived from pooled healthy human plasma. It is used to treat a range of conditions including primary immunodeficiency disorders (to provide passive immunity), immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), Kawasaki disease and other autoimmune or infectious diseases when more specific therapies are not available. The mechanism of action involves providing exogenous IgG antibodies that supplement the patient’s own immune system to fight infections and modulate abnormal immune responses. Human normal immunoglobulin is administered intravenously or subcutaneously depending on the formulation[1][2][4][8].
- Brand names
- FlebogammaGammagardHizentraGamunex-CGammakedOctagamPanzygaPrivigenGammaplexBivigamAsceniv
- Other names
- human immunoglobulin Gimmune globulin (human) IgG intravenous
02
Targets
C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)SIGNR1 (CD209 antigen-like protein B)
Beyond the preview
Go deeper on Human normal immunoglobulin G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human normal immunoglobulin G.